Boehringer Ingelheim and Eli Lilly have launched their new diabetes combination therapy Glyxambi across the US, offering patients a new option for blood glucose control.
News
FDA lifts clinical hold on Pfizer/Lilly’s tanezumab
Pfizer and Eli Lilly are getting ready to restart Phase III clinical trials for experimental chronic pain drug tanezumab, after US regulators lifted the partial clinical hold on the programme.
US orphan status for AB Science’s muscle-wasting drug
AB Science’s tyrosine kinase inhibitor masitinib has been awarded Orphan Drug status by the US Food and Drug Administration as a treatment for the rare degenerative disorder amyotrophic lateral sclerosis which causes progressive wasting and paralysis of voluntary muscles.
FDA panel backs GSK/Theravance inhaler for adults, not children
Advisors to the US Food and Drug Administration are backing approval of GlaxoSmithKline/Theravance’s BREO Ellipta inhaler for the treatment of asthma in adults, but not for children aged 12 to 17 years old.
Japanese filing for Amgen’s PCSK9 inhibitor Repatha
Amgen has filed its closely watched PCSK9 inhibitor Repatha (evolocumab) in Japan for the treatment of high cholesterol.
Lilly in 10-year cancer pact with China’s Innovent
Eli Lilly and Innovent Biologics have signed a major, ground-breaking 10-year deal to work together on the development and potential commercialisation of at least three new cancer treatments.
Pfizer’s Xeljanz hits targets in PhIII psoriasis trial
Pooled analysis of data from two Phase III trials with Pfizer’s JAK inhibitor Xeljanz (tofacitinib) add further support to the drug’s use as a treatment for moderate to severe psoriasis.
Prothena surges as early-stage Parkinson’s drug impresses
Prothena’s stock surged more than 40% after-hours yesterday as early-stage data sparked hope that the firm’s Roche-partnered experimental monoclonal antibody PRX002 could offer a new approach to treating Parkinson’s disease.
Sanofi and Evotec seal 250m-Euro strategic alliance
Sanofi and Evotec have now concluded negotiations over a five-year strategic alliance giving the German group 250 million Euros, including more than 40 million Euros upfront in cash.
AbbVie, C2N hook up in anti-tau antibodies deal
AbbVie has signed a deal with C2N Diagnostics to develop and commercialise the latter’s portfolio of anti-tau antibodies for the treatment of Alzheimer’s disease and other neurological disorders.
AstraZeneca sees the light on clinical trial transparency
AstraZeneca is embracing clinical trial transparency with the creation of a Scientific Review Board to independently assess requests for data.
Daiichi partners with AZ to sell Movantik in US
AstraZeneca has chosen Daiichi Sankyo to help sell its novel constipation drug Movantik (naloxegol) in the US, as the firm gears up for its launch in April.
Disclosure a real opportunity for the industry
The new disclosure rules on payments to doctors have come into force but there are likely to be teething problems as the industry begins to implement the new requirements, an industry expert says.
EXCLUSIVE: Healthcare at Home service levels back to normal
Service levels are now back to normal at UK homecare giant Healthcare at Home after last year’s move to outsource its drug distribution arrangements resulted in a stream of failed and late deliveries to patients.
Good news from Takeda’s AETHERA trial in Hodgkin lymphoma
Progression-free survival in Hodgkin lymphoma patients has been boosted when they take Adcetris (brentuximab vedotin), Phase III data from Takeda UK shows.
